Search Results
Your search for can matches 13753 pages
Showing 1651 - 1700Sara Hurvitz, MD, Joins Fred Hutch, University of Washington, Seattle
On August 1, 2023, Sara Hurvitz, MD, will assume the role of Senior Vice President of the Clinical Research Division at Fred Hutch and as Head of the newly united Division of Hematology and Oncology at the University of Washington Department of Medicine in Seattle. Dr. Hurvitz will report directly...
How ASCO’s 2023 Breakthrough Meeting Is Putting a Spotlight on Cutting-Edge Advances in Cancer Care Technology and Innovation
After a 4-year hiatus because of the COVID-19 pandemic, ASCO’s Breakthrough meeting is returning to Asia from August 3–5, 2023, in Yokohama, Japan, and will also be livestreamed (https://conferences.asco.org/breakthrough/welcome). Launched in 2019 in Bangkok, Thailand, “Breakthrough is ASCO’s...
A Telephone-Based Weight-Loss Intervention Induced Clinically Meaningful Weight Loss in Patients With Breast Cancer and Overweight or Obesity
Jennifer A. Ligibel, MD, FASCO, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, and colleagues conducted a randomized study to evaluate the impact of a telephone-based ...
A European Leader in Surgical Oncology, Isabel T. Rubio, MD, PhD, Shares Her Story and Sheds Light on the Challenges Ahead
In this installment of The ASCO Post’s Global Oncology series, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Isabel T. Rubio, MD, PhD, Head of Breast Surgical Oncology at Clinica Universidad de Navarra, Madrid. Dr. Rubio is active in many societies and is a founding member and...
Pathology Assessment During Mastectomy and Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer
Axillary management decisions made during surgery may be associated with aggressive treatment of limited nodal disease, according to data presented at a press briefing at the 2023 American Society of Breast Surgeons Annual Meeting.1 Results of a large National Cancer Database study revealed that...
Expert Point of View: Kohei Shitara, MD and Bradley Alexander McGregor, MD
At the ASCO session on the phase II DESTINY-PanTumor02 trial on T-DXd, the invited discussant, Kohei Shitara, MD, commented: “As expected, this trial demonstrated a very impressive response rate and duration of response” and “showed T-DXd [fam-trastuzumab deruxtecan-nxki] to be a potential new...
Expert Point of View: Ann S. LaCasce, MD, MMSc
Formal discussant of the SWOG S1826 abstract, Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, Boston, said she was “excited” by these results. “The data speak for themselves. Nivolumab plus AVD [doxorubicin, vinblastine, dacarbazine] should be the treatment of choice, with more...
A Call for Tailored Medical Services in Oncology Care for Older Deaf Patients
My father is deaf. Born deaf, he is now 75 years old. He uses his voice, but he sounds strange to a hearing person when he speaks. He uses lip-reading techniques to communicate. A year ago, he was diagnosed with Hodgkin lymphoma. We did his oncology itinerary together. My father cannot go alone to...
Expert Point of View: Pamela L. Kunz, MD and Corrie Marijnen, MD, PhD
Commenting at a press briefing, Pamela L. Kunz, MD, Director of the Center for Gastrointestinal Cancers and Chief of GI Medical Oncology at Smilow Cancer Hospital and Yale Cancer Center, New Haven, said the results of PROSPECT are “practice-changing” and “align incredibly well with the theme at...
Adjuvant Osimertinib Improves Overall Survival in Resectable EGFR-Mutated NSCLC
The phase III ADAURA trial previously found that adjuvant use of osimertinib improved disease-free survival for completely resected EGFR-mutated non–small cell lung cancer (NSCLC) in patients with stage IB, II, or IIIA disease.1 The final analysis of ADAURA, which was presented at the 2023 ASCO...
Medicaid Expansion May Be Linked to Increase in Palliative Care for Patients With Advanced Cancers
The expansion of Medicaid coverage under the Affordable Care Act may be associated with the largest increases in critical palliative care services for patients with advanced cancers in the United States, according to a new study published by Han et al in Health Affairs. The findings uncovered how...
COVID-19 Booster Doses May Strengthen Immunity in Patients With Lymphoma
Researchers have found that repeated COVID-19 vaccination may increase the vaccine’s effectiveness at preventing the infections in patients with lymphoma, particularly after four doses, according to a new study published by Wijaya et al in The Lancet. Background Patients with lymphoma often have...
Staging Laparoscopy May Help Identify Early Metastases in Patients With Pancreatic Cancer
Performing a minimally invasive staging laparoscopy on patients with newly diagnosed pancreatic cancer may help determine the stage and identify cancer metastases early, according to a novel study published by Gudmundsdottir et al in the Journal of the American College of Surgeons. The new findings ...
Patients Whose Pancreatic Cysts Remain Stable for 5 Years May Have Decreased Risk of Pancreatic Cancer
Investigators have called into question the health benefit of extended surveillance for patients whose pancreatic cysts have not changed size for at least 5 years and had no worrisome features, according to a new study published by Chhoda et al in Clinical Gastroenterology and Hepatology....
Investigators Identify Requirements to Potentially Optimize Cancer Survivorship Care for Patients in Rural Areas
The vast majority of cancer survivors may rely on primary care physicians for follow-up treatments, especially in rural areas, according to a new study published by Becevic et al in the Journal of Cancer Education. Background Patients often depend on their primary care physicians to help them...
CDCP1 May Be an Effective Therapeutic Target for Patients With Metastatic Bladder Cancer
Researchers have identified a new potential therapeutic target—the cell-surface tumor antigen CUB domain–containing protein 1 (CDCP1)—for patients with all subtypes of metastatic bladder cancer, according to findings presented by Chopra et al at the Society of Nuclear Medicine & Molecular...
Largest Human Breast Cell Atlas to Date May Offer Insights Into Mammary Biology
Researchers have created the world’s largest and most comprehensive atlas of normal breast tissue—the Human Breast Cell Atlas—which may provide an unprecedented understanding of mammary biology and help identify therapeutic targets for diseases such as breast cancer, according to a recent study...
Addition of External-Beam Radiation Therapy to Brachytherapy in Intermediate-Risk Prostate Cancer
In the phase III NRG Oncology/RTOG 0232 trial reported in the Journal of Clinical Oncology, Jeff M. Michalski, MD, MBA, FASTRO, and colleagues found no significant benefit in 5-year freedom from disease progression with the addition of external-beam radiation therapy (EBRT) to brachytherapy in...
Risk of Ovarian Cancer in Postmenopausal Patients With Polycystic Ovary Syndrome
Patients with polycystic ovary syndrome may not have a higher risk of ovarian cancer than those without the condition; however, postmenopausal patients with polycystic ovary syndrome may have twofold the risk of developing ovarian cancer, according to recent findings presented by Frandsen et al at...
Fertility in Female Survivors Treated for Hodgkin Lymphoma as Children
Female survivors treated for Hodgkin lymphoma may face declining fertility at a younger age, according to recent findings presented by Drechsel et al at the European Society of Human Reproduction and Embryology (ESHRE) 2023 Annual Meeting (Abstract O-083). The new research also suggested that the...
Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary
Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve...
LGBTQ+ Patients and Survivors of Cancer Expressed Concern Over Discrimination in Health-Care Settings, According to New Survey
About 50% of LGBTQ+ patients and survivors of cancer may be concerned about facing discrimination in a health-care setting, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). The new findings demonstrated that these concerns and experiences with...
Curettage and Cryosurgery May Be Effective for Patients With Basal Cell Carcinoma
The combination of curettage and cryosurgery may be a safe and effective treatment method for patients with basal cell carcinoma, according to a novel study published by Backman et al in the Journal of the American Academy of Dermatology. Background The incidence of skin cancer is continuing to...
FDA Approves Iopromide Injection for Contrast-Enhanced Mammography
Iopromide-300 and -370 (Ultravist), an iodine-based contrast agent, has been approved by the U.S. Food and Drug Administration (FDA) for contrast-enhanced mammography—making it the only contrast agent approved for this indication. The product can be used to visualize known or suspected lesions of...
Potential Role of ChatGPT-4 in Selecting Appropriate Imaging Tests for Breast Cancer Screenings and Breast Pain
Investigators have found that artificial intelligence (AI) language models like OpenAI’s ChatGPT may accurately identify appropriate imaging tests for breast cancer screenings and breast pain, according to a recent study published by Rao et al in the Journal of the American College of Radiology....
Pretherapy Imaging and Dosimetry May Inform Personalized Treatment Strategies for Patients With Refractory Differentiated Thyroid Cancer
A combination of pretherapy imaging and dosimetry may help patients with refractory differentiated thyroid cancer obtain the maximum benefit from radioactive iodine treatments following redifferentiation therapy, according to a novel study published by Taprogge et al in The Journal of Nuclear...
EGFR and ERBB2 Mutations May Be Associated With Lenvatinib-Resistant Hepatocellular Carcinoma
A genetic marker involving the EGFR and ERBB2 genes may be predictive of which patients with hepatocellular carcinoma are most likely to develop resistance to lenvatinib, according to a study published by Lim et al in Gastroenterology. The new findings could help researchers develop alternative...
Traditional Chinese Medicine Herbal Formula Suan Zao Ren Tang for Insomnia
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
Rwanda’s Vision for Increasing Cervical Cancer Prevention One Village at a Time
Cervical cancer is a serious problem in many low- and middle-income countries such as the African country of Rwanda. Although the cervical cancer rate in Rwanda remains more than twice the U.S. rate, there has been improvement in recent years that cancer research organizations can learn from to...
Expert Point of View: Zeynep Eroglu, MD
The formal discussant of the phase II SWOG S1512 trial was Zeynep Eroglu, MD, of the Department of Cutaneous Oncology at the Moffitt Cancer Center in Tampa, Florida. She congratulated Dr. Kendra and her coauthors for conducting a study in such a rare tumor. “I think we can say desmoplastic melanoma ...
ASCO Issues Clinical Guidance for Treating Gastrointestinal Cancers Amid Acute Drug Shortages
ASCO has issued new clinical guidance for treating patients with gastrointestinal cancers amid a nationwide shortage of carboplatin and cisplatin. The two chemotherapy agents, in extremely short supply, are essential to treating an array of gastrointestinal cancers—such as esophageal, pancreatic,...
In Case You Missed It: Brief Highlights From Studies Presented During AACR 2023
Presented here are some highlights of preliminary studies presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. These presentations provide signals for the utility of an off-the-shelf chimeric antigen receptor (CAR) T-cell product in renal cell carcinoma, an...
Thinking Outside the Box: Embracing Innovation and Collaboration in Oncology
In the ever-evolving landscape of oncology care, embracing innovation and creative problem-solving have become crucial factors for success. At the 2023 Community Oncology Alliance Annual Meeting, a panel discussion tackled the complexities and opportunities associated with implementing value-based...
Building a More Equitable Oncology Practice: The Path to Better Patient Outcomes
By embracing diversity, equity, and inclusion (DEI), oncology practices can work toward better patient outcomes and a more effective health-care system, according to Richard L. Martin III, MD, MPH, Medical Director of Health Equity and Community Engagement at Tennessee Oncology. At the 2023...
Medicaid Expansion Associated With a Reduction in Mortality for Black Patients With Gastrointestinal Malignancies
A study investigating the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal malignancies has found that the initiative was associated with a greater reduction in 2-year mortality rates among Black patients living in states with Medicaid expansion...
FDA Grants Full Approval to Blinatumomab for MRD-Positive B-Cell Precursor ALL
On June 21, the U.S. Food and Drug Administration (FDA) approved the supplemental biologics license application for blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission...
Expert Point of View: Jose Alejandro Rauh-Hain, MD, MPH
“This is an impressive presentation,” said formal discussant Jose Alejandro Rauh-Hain, MD, MPH, of The University of Texas MD Anderson Cancer Center, Houston. “Radical hysterectomy has intraoperative and postoperative complications that include gastrointestinal and genitourinary long-term...
De-escalation of Surgery Feasible for Selected Patients With Low-Risk, Early-Stage Cervical Cancer
Many patients with early-stage, low-risk cervical cancer may be spared the side effects associated with radical hysterectomy and undergo simple hysterectomy with pelvic lymph node dissection instead, according to results of the international phase III SHAPE study presented at the 2023 ASCO Annual...
Expert Point of View: Roisin E. O’Cearbhaill, MD
Formal discussant of this late-breaking presentation, Roisin E. O’Cearbhaill, MD, of Memorial Sloan Kettering Cancer Center, New York, commented: “MIRASOL is confirmatory of SORAYA, the trial that led to FDA accelerated approval. The impressive data of MIRASOL show an overall survival advantage in ...
Prostate Cancer Disparities and the ‘Last Mile’ Problem
Prostate cancer is the most commonly diagnosed cancer in men in the United States and the second-leading cause of cancer death.1 It also offers a sobering example in the national conversation on racial disparities in cancer care. Despite a deeper scientific understanding of the disease—as well as ...
Expert Point of View: Rita Nanda, MD
“I expect the NATALEE trial results will change clinical practice,” stated ASCO expert Rita Nanda, MD, Director of the Breast Oncology Program at University of Chicago Medicine. “Three different CDK4/6 inhibitors have all been shown to improve progression-free survival in the first- and second-line ...
Expert Point of View: Rimas Vincas Lukas, MD
Rimas Vincas Lukas, MD, of Northwestern University, was the formal discussant of this plenary session abstract on the INDIGO trial findings. “Because of its slowly progressive nature, glioma is insidious. The impact of the disease and its treatments has important consequences for patients,...
INDIGO Trial: IDH Inhibitor Improves Progression-Free Survival in Grade 2 IDH1/2-Mutated Gliomas
The oral IDH1/2 inhibitor vorasidenib significantly improved progression-free survival in patients with grade 2 gliomas expressing IDH1/2 mutations in the phase III INDIGO trial. These results, which were reported by lead author Ingo K. Mellinghoff, MD, FACP, of Memorial Sloan Kettering Cancer...
Surgeon Quality Metrics and Survival After Curative-Intent Surgery for NSCLC
In a study reported in the Journal of Clinical Oncology, Ray et al found that higher surgeon quality (determined by intermediate outcome metrics) was associated with improved overall survival among patients undergoing curative resection for non–small cell lung cancer (NSCLC). The investigators...
Aromatase Inhibitors May Limit Effectiveness of Weight Loss Medications in Breast Cancer Survivors
Aromatase inhibitors may interfere with the efficacy of weight loss medications in breast cancer survivors, according to a new study presented by Fansa et al at the 2023 Endocrine Society Annual Meeting. Background Aromatase inhibitors are designed to block the activity of the aromatase enzyme,...
Older Breast Cancer Survivors May Experience Accelerated Aging, Worse Functional Outcomes Following Chemotherapy
Investigators have found that older breast cancer survivors—particularly those exposed to chemotherapy—may experience greater epigenetic aging and poorer outcomes than those without a history of cancer, according to a new study published by Rentscher et al in Cancer. Background Epigenetic aging...
FDA Grants Accelerated Approval to Glofitamab-gxbm for Relapsed or Refractory DLBCL
On June 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma,...
Impact of Historic Redlining Practices on Cancer Screening Rates
Although redlining was outlawed more than 50 years ago, individuals who currently live in historically redlined areas may be less likely to be screened for breast cancer, colorectal cancer, and cervical cancer than individuals who live in areas not associated with redlining practices, according to...
Study Evaluates Clinical Utility of Novel Liquid Biopsy-Breast Cancer Methylation Prototype Assay
A novel, automated liquid biopsy test—the Liquid Biopsy for Breast Cancer Methylation assay—may be effective at predicting early disease progression and potential survival outcomes in patients with metastatic breast cancer after as little as 1 month of treatment, according to a study published by...
Research Sheds Light on the Evolution of Precursor Conditions to Multiple Myeloma
Researchers have shared novel insights into the evolution of multiple myeloma from precursor disease, which may help physicians better identify patients whose disease is likely to progress as well as develop new interventions, according to a recent study published by Dang et al in Cancer Cell. How...
